case_images: PMC3275456_01
case_images: Contrast-enhanced computed tomography scans before surgical resection. (A) Arterial phase showed a large hypervascular lesion extending from the left lobe to the anterior segment of the right lobe. (B) The left branch of the portal vein was not identified as being involved in the tumor, invasion of the portal vein was suspicious (white arrow).
case_images: 1752-1947-6-38-1.jpg
case_images: PMC3275456_01_1752-1947-6-38-1.jpg
case_images: F1
case_images: Enhanced computed tomography (CT) revealed a large liver tumor 15 cm in diameter extending from the left lobe to the anterior segment of the right lobe, which was enhanced in the arterial phase and washed out in the equilibrium phase, which is typical of HCC (Figure 1).
case_images: (A1-3) Contrast-enhanced computed tomography scans before restarting sorafenib. (A1, 2) Multiple metastatic lesions were observed in the lung (black arrows). (A3) Local tumor progressions were also observed in the cut surface of the liver (white arrows). (B1-3) Contrast-enhanced computed tomography scans six months after restarting sorafenib. (B1) The growth and new metastatic lesions were observed in the lung (black arrows). (B2) In addition, mediastinal lymph node metastases were observed anew (white arrows). (B3) Local tumor progressions were unequivocally observed (white arrows). (C1-3) Contrast-enhanced computed tomography scans 10 months after restarting sorafenib. (C1) Metastatic lesions in the lung shrunk or disappeared (black arrows). (C2-3) Mediastinal lymph node metastases and local tumor progressions completely disappeared (white arrows).
case_images: 1752-1947-6-38-2.jpg
case_images: PMC3275456_01_1752-1947-6-38-2.jpg
case_images: F2
case_images: CT scan (Figure 2C1-3), and the patient remains stable on sorafenib at a dose of 400 mg per day. Currently, he is working full time and is in excellent general health.